SCHEMBL4313733

SCHEMBL4313733

CC(=CCS)Cc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 2/20 0.41
CES2 O00748 1/20 0.41
AKR1B1 P15121 1/20 0.41
IDO1 P14902 1/20 0.41
ALDH1A1 P00352 3/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
TSHR P16473 3/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
TP53 P04637 1/20 0.36
TRPA1 O75762 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
FNTA P49354 1/20 0.35
FNTB P49356 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9189820 0.82 CA2 (0.42) ALDH1A1FNTAFNTB
SCHEMBL10296055 0.81 CES1 (0.43) CES1CES2AKR1B1ALDH1A1MEN1
SCHEMBL11074865 0.81 CES1 (0.43) CES1CES2AKR1B1ALDH1A1MEN1
SCHEMBL1071378 0.81 CES2 (0.43) CES1CES2AKR1B1ALDH1A1MEN1
SCHEMBL11074864 0.81 CES1 (0.43) CES1CES2AKR1B1ALDH1A1MEN1
SCHEMBL8960351 0.80 KMT2A (0.37) MEN1KMT2AHPGD
SCHEMBL8565964 0.80 CTBP2 (0.44) IDO1HDAC8HDAC6TSHR
SCHEMBL8566370 0.80 BCL2 (0.35) IDO1KMT2AHDAC8HDAC6TP53
SCHEMBL28806825 0.79 CES1 (0.41) CES1CES2AKR1B1ALDH1A1MEN1
SCHEMBL563812 0.79 CES2 (0.41) CES1CES2AKR1B1ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006059345-A2 PROCESS FOR THE PREPARATION OF ACETYLENIC RETINOID SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2006-06-08 WO claimed
WO-2006059345-A3 PROCESS FOR THE PREPARATION OF ACETYLENIC RETINOID SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2009-10-15 WO disclosed
US-7414143-B2 Process for the preparation of 4,4-dimethyl-6-ethynylthiochroman GLENMARK PHARMACEUTICALS LIMITED (IN) 2008-08-19 US disclosed
WO-2006059345-A2 PROCESS FOR THE PREPARATION OF ACETYLENIC RETINOID SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2006-06-08 WO disclosed
WO-2006059345-A2 PROCESS FOR THE PREPARATION OF ACETYLENIC RETINOID SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2006-06-08 WO disclosed
US-6963002-B2 Process for the preparation of 4,4-dimethyl-6-ethynylthiochroman GLENMARK PHARMACEUTICALS LIMITED (US) 2005-11-08 US disclosed
US-20050240029-A1 Process for the preparation of 4,4-dimethyl-6-ethynylthiochroman GLENMARK PHARMACEUTICALS LIMITED (IN) 2005-10-27 US disclosed
WO-2005003125-A1 PROCESS FOR THE PREPARATION OF 4,4-DIMETHYL-6-ETHYNYLTHIOCHROMAN GLENMARK PHARMACEUTICALS LIMITED (US) 2005-01-13 WO disclosed
US-20050004373-A1 Process for the preparation of 4,4-dimethyl-6-ethynylthiochroman GLENMARK GENERICS LTD. (IN) 2005-01-06 US disclosed
EP-0785782-B1 USE OF DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY ALLERGAN INC (US) 2004-09-08 EP disclosed
US-5234926-A Skin disorders ALLERGAN, INC. (US) 1993-08-10 US disclosed
EP-0284288-B1 DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID LIKE ACTIVITY ALLERGAN, INC (US) 1992-05-27 EP disclosed
US-5089509-A Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity ALLERGAN, INC. (US) 1992-02-18 US disclosed
EP-0290130-B1 ACETYLENES DISUBSTITUTED WITH A PHENYL GROUP AND A HETEROBICYCLIC GROUP HAVING RETINOID LIKE ACTIVITY ALLERGAN, INC (US) 1991-11-06 EP disclosed
US-5053523-A Chemical intermediate for compounds having retinoic acid-like activity ALLERGAN, INC. (US) 1991-10-01 US disclosed
US-5023341-A Acetylene thiochroman ALLERGAN, INC. (US) 1991-06-11 US disclosed
EP-0419132-A2 Process and intermediates for preparing compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity ALLERGAN, INC. (US) 1991-03-27 EP disclosed
US-4810804-A PSORIASIS ALLERGAN, INC. (US) 1989-03-07 US disclosed
EP-0290130-A1 Acetylenes disubstituted with a phenyl group and a heterobicyclic group having retinoid like activity ALLERGAN, INC (US) 1988-11-09 EP disclosed
EP-0284288-A1 Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity ALLERGAN, INC (US) 1988-09-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050240029-A1 Process for the preparation of 4,4-dimethyl-6-ethynylthiochroman YAP1, SDHA, SDHB CES1 1709/4885CES2 3333/4885AKR1B1 466/4885
US-20050004373-A1 Process for the preparation of 4,4-dimethyl-6-ethynylthiochroman YAP1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SDHA CES1 1764/4885CES2 3329/4885AKR1B1 544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.